Adherium Limited Secures $900,000 in Capital Raise to Boost Hailie Smartinhaler Rollout

Highlights

• Adherium Limited (ASX: ADR) has secured $900,000 through the issuance of approximately 900,000 convertible notes, with key support from Phillip Asset Management Limited and Trudell Medical Limited.
• The capital raise aims to fund the expansion of Adherium's Hailie® Smartinhaler® platform in the United States and support its general working capital needs.
• Shareholder approval for the convertible notes will be sought at the 2025 Annual General Meeting, with terms including a 10% interest rate and conversion options tied to capital raises or maturity.

Capital Raise Details

Adherium Limited (ASX: ADR), a leading digital health company based in Melbourne, has successfully secured firm commitments to raise $900,000 through the issuance of approximately 900,000 convertible notes. At the time of writing, the company has announced that each investor will also receive one attaching option for every two shares issued under the convertible notes, adding further value to their investment. The capital raise was supported by key investors, including Phillip Asset Management Limited and Trudell Medical Limited, with each contributing $450,000. This financing will help Adherium progress the deployment of its innovative Hailie® Smartinhaler® platform in the United States, as well as support its general working capital needs.

Shareholder Approval and Terms

The company plans to seek shareholder approval for these convertible notes during its 2025 Annual General Meeting. Under the agreement, the subscribers have agreed to advance the subscription amount as a loan, which will be converted into convertible notes following shareholder approval. The terms mirror those of the 2025 convertible notes issued earlier to Trudell Medical Limited, Philip Asset Management Limited, and K One W One Limited in March 2025. Key terms of the notes include a maturity date set nine months from issuance and an interest rate of 10% per annum. Investors will have the flexibility to convert these notes into ordinary shares at any point before the maturity date, with options provided for conversion based on certain conditions, including a capital raise of at least $5 million.

Strategic Outlook

The $900,000 funding boost is intended to drive the expansion of Adherium's Hailie® platform, designed to improve medication adherence and health outcomes for respiratory patients. With its proprietary technology gaining traction, the company aims to solidify its footprint in the U.S. market while advancing its digital health solutions.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com